S

Sanofi

Global pharma company; vaccines and R&D

Zone Development Manager - Hematology

Full-TimeDeadline 11/30/26
$113.3k - $188.8k/yr+ Annual bonus + Company car
Mid
Bachelor's, MBA
Cambridge, MA, USA+1 moreMore locations: Denver, CO, USA
RemoteApproximately 40% travel is expected; candidates should reside in the West or Central region or the Boston/Cambridge area.

About the job

Requirements
  • A bachelor's degree (BA/BS) is required; life sciences or business is preferred, and an MBA is a plus.
  • At least 4 years of industry experience in pharmaceutical, biotech, or medical device roles such as sales, commercial operations, marketing, training, or project management.
  • Ability to learn and apply technical and scientific product information.
  • Ability to travel to meetings, trainings, and programs as required, with approximately 40% travel expected.
  • A valid driver's license is required.
  • Must reside within the West or Central region, or in the Boston/Cambridge, Massachusetts area.
Responsibilities
  • Support two Divisional General Managers and a combined field team of Regional Business Directors, Account Business Managers, Key Account Managers, and Thought Leader Liaisons.
  • Create agendas for key divisional meetings, execute timely follow-up, and assign actionable items with clear accountability to appropriate stakeholders.
  • Coordinate promotional programming, congress activities, and budget allocation to maximize business impact.
  • Train field teams on key business tools and systems, including Veeva and analytics platforms, and pilot new initiatives before broader rollout.
  • Implement and scale account planning initiatives across the division to optimize customer engagement.
  • Participate in key work streams, including SFAST, marketing partnerships, and special projects, to ensure the field voice is represented in home office decisions.
  • Track and analyze performance metrics across account, divisional, regional, and territory levels to generate actionable insights for strategic decision-making.
  • Conduct sales and gap analyses to determine the effectiveness of sales strategy and recommend solutions to improve sales performance.
  • Provide ongoing national, divisional, regional, and territory-level analysis to identify ways to optimize overall performance.
  • Evaluate current analytics tools with the Divisional General Manager and provide ongoing input for improvement.
  • Share analytics best practices across the division and nation in collaboration with the Divisional General Manager.
  • Collaborate with training and field teams to develop comprehensive POAs aligned with organizational goals.
  • Support planning and successful execution of POA meetings with the POA Planning Group.
  • Participate in field working groups, including SFAST, IC, Cross-Functional Teams, Data Champs, and Culture Team initiatives.
  • Support New Hire Training programs and Account Business Manager field training initiatives.
Desired Qualifications
  • Oncology commercial experience.
  • Experience in field-based training, project management, commercial operations, sales, sales leadership, or marketing.
  • A proven track record as a high-level performer with demonstrated readiness for expanded responsibility.
  • Strong business acumen and the ability to develop and execute business plans that achieve commercial goals.
  • Verbal and written communication skills, including executive-level presentation ability.
  • Cross-functional collaboration skills and the ability to influence without authority.
  • Formal or informal leadership experience.
  • Career aspirations toward home office leadership, field management, or senior commercial roles.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)